Molecular oncology, 8(3), 679-688. Elsevier Draht, M X G, Smits, K M, Tournier, B, Jooste, V, Chapusot, C, Carvalho, B, Cleven, A H G, Derks, S, Wouters, K A D, Belt, E J T H, Stockmann, H B A C, Bril, H, Weijenberg, M P, van den Brandt, P A, de Bruine, A P, Herman, J G, Meijer, G A, Piard, F, Melotte, V & van Engeland, M 2014, ' Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients ', Molecular oncology, vol. 8, no. 3, pp. 679-688 . https://doi.org/10.1016/j.molonc.2014.01.011
Cleven, A H G, Derks, S, Draht, M X G, Smits, K M, Melotte, V, Van Neste, L, Tournier, B, Jooste, V, Chapusot, C, Weijenberg, M P, Herman, J G, De Bruïne, A P & Van Engeland, M 2014, ' CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer ', Clinical Cancer Research, vol. 20, no. 12, pp. 3261-3271 . https://doi.org/10.1158/1078-0432.CCR-12-3734 Clinical Cancer Research, 20(12), 3261-3271. American Association for Cancer Research Inc.
Epigenomics, 4(2), 179-194. Future Medicine Ltd. Draht, M X G, Riedl, R R, Niessen, H, Carvalho, B, Meijer, G A, Herman, J G, van Engeland, M, Melotte, V & Smits, K M 2012, ' Promoter CpG island methylation markers in colorectal cancer: the road ahead ', Epigenomics, vol. 4, no. 2, pp. 179-194 . https://doi.org/10.2217/EPI.12.9